BioSpace News Archive

Leap Therapeutics, Inc. (Nasdaq:LPTX) today announced that the first patient has been enrolled in the randomized controlled Part C of the ongoing DisTinGuish study to evaluate DKN-01, Leap’s anti-Dickkopf-1 (DKK1) antibody, in combination with tislelizumab, BeiGene’s anti-PD-1 antibody, and chemotherapy compared to a tislelizumab and chemotherapy control arm, in patients with gastric or gastroesophageal junction cancer (G/GEJ).

ATP, a leader in life sciences venture capital, today announced the launch of Ascidian Therapeutics, a biotechnology company built and developed by ATP and funded with a $50 million Series A financing.

Willow Biosciences Inc. is pleased to announce that it has completed proof of concept work, and has started yeast strain optimization and process development toward commercial production of astaxanthin, a powerful, naturally occurring, antioxidant compound that is used in diverse industries such as animal feed, food & nutrition, and cosmetics.

Ionis Pharmaceuticals, Inc. announced that it has entered into an agreement with Sudberry Properties to develop and lease a new development chemistry and manufacturing site in Oceanside, Calif.

Merck announced that Health Canada has granted approval for KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, as monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC).

ZAP Surgical Systems, Inc. announced that the University Hospital in Olsztyn, in collaboration with the University of Warmia and Mazury in Olsztyn, will become the first center in Poland and Eastern Europe to offer completely non-invasive brain tumor treatments with the ZAP-X® Gyroscopic Radiosurgery® platform.

Vita Therapeutics today announced the completion of a $31 million Series B financing.

Seres Therapeutics, Inc. announced today that it will be presenting data from its ECOSPOR IV trial of SER-109, an investigational microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI), at two leading industry conferences.

Antibe Therapeutics Inc. is pleased to announce a major advance in otenaproxesul’s formulation that promises to increase its therapeutic benefit and commercial potential. Accordingly, the Company has filed a patent application that strengthens the drug’s IP protection to 2042.

Theratechnologies Inc. today announced that the Company will present data from tissue microarrays showing high expression of SORT1, the target for Theratechnologies’ oncology platform, in several cancer types.